Ravulizumab - Alexion Pharmaceuticals

Drug Profile

Ravulizumab - Alexion Pharmaceuticals

Alternative Names: ALXN 1210; ALXN 1810

Latest Information Update: 31 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alexion Pharmaceuticals
  • Class Monoclonal antibodies
  • Mechanism of Action Complement C5 inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Paroxysmal nocturnal haemoglobinuria; Haemolytic uraemic syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Paroxysmal nocturnal haemoglobinuria
  • Phase III Haemolytic uraemic syndrome
  • Clinical Phase Unknown Myasthenia gravis
  • Preclinical IgA nephropathy
  • No development reported Immunological disorders

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for phase-I development in Immunological-disorders in USA
  • 26 Jul 2018 Alexion files Clinical Trial Application of ALXN 1810 for Hemolytic Uremic Syndrome in European union
  • 26 Jul 2018 Alexion Pharmaceuticals plans a phase I trial for Paroxysmal nocturnal haemoglobinuria in the second half of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top